3.
Currently, the standard treatment for the cognitive decline that occurs with Alzheimer’s disease (AD) has been the use of acetylcholinesterase inhibitors. However, the improvement produced by these medications has been modest. Current research has focused on the development of cholinergic agonists and, in particular, agents that bind on one of the subtypes of the muscarinic acetylcholine (mACh) receptor. Xanomeline is one of these new agents, and it binds at which of the mACh receptors?